These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17664068)

  • 1. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
    Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition.
    Jerome KD; Rucker PV; Xing L; Shieh HS; Baldus JE; Selness SR; Letavic MA; Braganza JF; McClure KF
    Bioorg Med Chem Lett; 2010 Jan; 20(2):469-73. PubMed ID: 19969459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.
    Mavunkel BJ; Perumattam JJ; Tan X; Luedtke GR; Lu Q; Lim D; Kizer D; Dugar S; Chakravarty S; Xu YJ; Jung J; Liclican A; Levy DE; Tabora J
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1059-62. PubMed ID: 20031411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
    Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
    Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
    Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
    Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
    Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.